• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

Introduction to 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole (CAS No. 1388023-10-6)

5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole, identified by the CAS number 1388023-10-6, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the benzimidazole family, a class of molecules known for their broad spectrum of biological activities and utility in drug development. The structural features of 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole, including the presence of bromine, chlorine, and fluorine substituents, contribute to its unique chemical properties and potential applications in synthetic chemistry and drug discovery.

The benzimidazole core is a privileged scaffold in medicinal chemistry, exhibiting activities ranging from antiviral and anticancer to anti-inflammatory and antimicrobial effects. The introduction of halogen atoms into the benzimidazole ring enhances its pharmacological profile by influencing electronic distribution, lipophilicity, and interactions with biological targets. Specifically, the bromo and chloro substituents at the 2-position and 5-position, respectively, along with the fluoro group at the 7-position, create a multifaceted molecular entity that is likely to interact with enzymes and receptors in complex ways.

In recent years, there has been a surge in research focused on developing novel benzimidazole derivatives as therapeutic agents. The structural modifications introduced in 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole are particularly intriguing because they allow for fine-tuning of biological activity. For instance, the electron-withdrawing nature of halogen atoms can modulate the reactivity of the benzimidazole ring, making it more susceptible to functionalization or enabling specific interactions with biological targets. This has led to increased interest in exploring its potential as a lead compound for drug development.

One of the most compelling aspects of 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole is its versatility in synthetic applications. The presence of multiple reactive sites allows chemists to employ various coupling reactions, nucleophilic substitutions, or metal-catalyzed transformations to generate derivatives with tailored properties. This flexibility is particularly valuable in medicinal chemistry, where structural optimization is often required to improve potency, selectivity, and pharmacokinetic profiles.

Recent studies have highlighted the importance of halogenated benzimidazoles in drug discovery. For example, compounds containing bromine and chlorine substituents have been shown to exhibit enhanced binding affinity to certain protein targets due to their ability to form multiple hydrogen bonds or engage in π-stacking interactions. The fluoro group further contributes to this property profile by increasing metabolic stability and lipophilicity, which are critical factors for drug efficacy.

The pharmaceutical industry has been particularly interested in halogenated benzimidazoles for their potential as kinase inhibitors. Kinases are enzymes that play a crucial role in cell signaling pathways and are frequently implicated in diseases such as cancer. By designing molecules that selectively inhibit specific kinases, researchers aim to develop treatments that target the underlying mechanisms of these diseases. 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole represents a promising starting point for such efforts due to its structural features that mimic known kinase inhibitors.

Another area where 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole shows promise is in the development of antiviral agents. Viruses rely on host cellular machinery for replication, making it possible to target viral enzymes or receptors without causing significant toxicity to host cells. The unique electronic properties of halogenated benzimidazoles make them suitable candidates for disrupting viral replication cycles by inhibiting key viral enzymes or interfering with viral entry into host cells.

The synthesis of 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole involves multi-step organic reactions that highlight its synthetic utility. Typically, the process begins with the formation of the benzimidazole core through condensation reactions between o-amino benzoic acid derivatives or other suitable precursors. Subsequent halogenation steps introduce the bromine and chlorine atoms at specific positions on the ring. Finally, fluorination is carried out using appropriate fluorinating agents under controlled conditions to yield the desired product.

The purity and yield of 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole are critical factors that influence its applicability in pharmaceutical research. High-purity compounds are essential for accurate biological testing and ensure that observed effects are due to the intended molecule rather than impurities. Advances in synthetic methodologies have enabled researchers to produce high-quality batches of this compound, facilitating further exploration of its potential applications.

In conclusion, 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole (CAS No. 1388023-10-6) is a structurally interesting compound with significant potential in pharmaceutical research. Its unique combination of halogen substituents makes it a versatile scaffold for developing novel therapeutic agents targeting various diseases. As research continues to uncover new biological activities and synthetic strategies for this class of compounds, 5-Bromo-2-chloro-7-fluoro-1H-benzo[d]imidazole is likely to remain a valuable tool in drug discovery efforts worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)